Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Abatacept in Active Proliferative Lupus Nephritis
NCT00430677Phase 3Terminated
- Sponsor
- Bristol Myers Squibb
- Start
- Jun 2007
- Primary completion
- Sep 2010
- Modality
- Fc-Fusion Proteins
- Countries
- 18
01
Overview
Phase 3, randomised, double-blind trial of abatacept in lupus nephritis (LN) (3 arms), sponsored by Bristol Myers Squibb. Primary endpoint: Time to First Confirmed Complete Renal Response at 12 months. Started Jun 2007; status: terminated.
02
Drugs
abatacept
03
Conditions
lupus nephritis (LN)
Beyond the preview
Go deeper on NCT00430677.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00430677.